Published in Br J Cancer on March 16, 2010
TLR-based immune adjuvants. Vaccine (2010) 2.10
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78
EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer (2012) 1.63
Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer (2016) 1.31
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.30
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27
Therapeutic cancer vaccines. J Clin Invest (2015) 1.23
Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med (2014) 1.21
Therapy of human papillomavirus-related disease. Vaccine (2012) 1.11
TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers. Cancer Immunol Immunother (2012) 1.01
Targeted treatments for cervical cancer: a review. Onco Targets Ther (2012) 1.00
A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3). Gynecol Oncol (2015) 0.98
A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother (2012) 0.97
Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs (2012) 0.96
Immunologic treatments for precancerous lesions and uterine cervical cancer. J Exp Clin Cancer Res (2014) 0.96
T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. Int J Cancer (2014) 0.93
Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ. Clin Cancer Res (2014) 0.93
Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res (2013) 0.92
Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice. Mucosal Immunol (2012) 0.90
New Approaches to Immunotherapy for HPV Associated Cancers. Cancers (Basel) (2011) 0.89
Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines (Basel) (2014) 0.89
Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. J Biomed Sci (2010) 0.89
The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools. Cancer Immunol Immunother (2012) 0.88
The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Expert Rev Clin Pharmacol (2011) 0.88
Immune therapy for human papillomaviruses-related cancers. World J Clin Oncol (2014) 0.86
Two distinct pathways to development of squamous cell carcinoma of the vulva. J Skin Cancer (2010) 0.85
Perspectives for therapeutic HPV vaccine development. J Biomed Sci (2016) 0.85
Tailored immunotherapy for HPV positive head and neck squamous cell cancer. Oral Oncol (2013) 0.84
Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. J Gynecol Oncol (2016) 0.83
Immunotherapy of human papilloma virus induced disease. Open Virol J (2012) 0.83
Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions. PLoS One (2014) 0.81
Major clinical research advances in gynecologic cancer in 2015. J Gynecol Oncol (2016) 0.81
Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines. Clin Vaccine Immunol (2015) 0.80
A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3. Oncoimmunology (2015) 0.80
Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer. PLoS One (2015) 0.79
Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination. Cancer Immunol Immunother (2016) 0.79
Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines (2016) 0.79
Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (shuffling). PLoS One (2014) 0.78
Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions. J Int AIDS Soc (2015) 0.78
A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing Tumors. J Immunother (2015) 0.78
Early Defensive Mechanisms against Human Papillomavirus Infection. Clin Vaccine Immunol (2015) 0.78
Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease. Cell Biosci (2016) 0.77
Recent advances in the study of HPV-associated carcinogenesis. Virol Sin (2015) 0.77
VIN usual type-from the past to the future. Ecancermedicalscience (2015) 0.77
Tumour virus vaccines: hepatitis B virus and human papillomavirus. Philos Trans R Soc Lond B Biol Sci (2017) 0.76
Developments in L2-based human papillomavirus (HPV) vaccines. Virus Res (2016) 0.76
HPV Infection-Associated Cancers: Next-Generation Technology for Diagnosis and Treatment. Cancer Immunol Res (2014) 0.76
Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies. Clin Vaccine Immunol (2015) 0.76
Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy. Ther Adv Vaccines (2017) 0.75
Monitoring of the Immune Dysfunction in Cancer Patients. Vaccines (Basel) (2016) 0.75
Treatments aim to topple papillomavirus before cancer begins. Nat Med (2010) 0.75
Vulval cancer and HPV vaccination in recurrent disease. Clin Case Rep (2014) 0.75
Progress and prospects for L2-based human papillomavirus vaccines. Expert Rev Vaccines (2016) 0.75
Non-responders to topical imiquimod followed by vaccination therapy in VIN patients may be due to the level of IL10. Br J Cancer (2010) 0.75
The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res (2016) 0.75
Adjuvants for peptide-based cancer vaccines. J Immunother Cancer (2016) 0.75
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol (1998) 9.43
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest (2005) 5.30
Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med (2008) 4.33
Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer (2009) 4.28
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02
Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer (2006) 3.93
Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res (2004) 1.90
Imiquimod: mode of action. Br J Dermatol (2007) 1.70
Immunobiology of HPV and HPV vaccines. Gynecol Oncol (2008) 1.66
Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double-blinded study. Gynecol Oncol (2007) 1.57
Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res (2004) 1.55
Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A (2007) 1.53
Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 1.51
Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5-aminolevulinic acid. Gynecol Oncol (2001) 1.51
Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res (2004) 1.50
Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol (2005) 1.31
Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res (2005) 1.30
Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res (2001) 1.26
Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine (2002) 1.25
Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res (2003) 1.24
Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection. Int J Gynecol Cancer (2009) 1.13
Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine (2004) 1.11
Cancer vaccines and immunotherapy. Br Med Bull (2002) 1.07
Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine (2008) 1.05
Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. Clin Cancer Res (2008) 1.05
Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol (2005) 1.00
Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia. Gynecol Oncol (2007) 0.98
Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16. J Immunol (2009) 0.98
Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells. Vaccine (2008) 0.94
Clinical responses to Cidofovir applied topically to women with high grade vulval intraepithelial neoplasia. Gynecol Oncol (2005) 0.89
Correlates of sexual function following vulvar excision. Gynecol Oncol (2007) 0.88
Vulvo-vaginal cancers: risks, evaluation, prevention and early detection. Obstet Gynecol Clin North Am (2007) 0.87
Photodynamic treatment for lower genital tract intraepithelial neoplasia. Lancet (1998) 0.85
[Epidemiology of vulvar intra-epithelial neoplasias]. Gynecol Obstet Fertil (2007) 0.85
Contribution of demographic, psychological and disease-related factors to quality of life in women with high-grade vulval intraepithelial neoplasia. Gynecol Oncol (2008) 0.84
Association between human leukocyte antigen polymorphism and human papillomavirus 16-positive vulval intraepithelial neoplasia in British women. Cancer Res (2003) 0.84
Smoking increases the risk of high-grade vaginal intraepithelial neoplasia in women with oncogenic human papillomavirus. Gynecol Oncol (2008) 0.82
Characterizing T-cell response in low-grade and high-grade vulval intraepithelial neoplasia, study of CD3, CD4 and CD8 expressions. Gynecol Oncol (2004) 0.81
Sexual function and somatopsychic reactions after local excision of vulvar intra-epithelial neoplasia. Acta Obstet Gynecol Scand (1992) 0.81
Failure of isotretinoin and interferon-alpha combination therapy for HPV-linked severe vulvar dysplasia. A report of two cases. J Reprod Med (1998) 0.79
[Photodynamic therapy in vulvar intraepithelial neoplasia]. Ginekol Pol (2008) 0.78
Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J (1995) 7.60
Randomised trial of hysterectomy, endometrial laser ablation, and transcervical endometrial resection for dysfunctional uterine bleeding. BMJ (1994) 5.76
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol (1993) 5.12
Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet (1997) 4.38
Management of women with mild and moderate cervical dyskaryosis. BMJ (1994) 3.65
Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem (1992) 3.48
Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation (1999) 3.35
Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today (1997) 2.89
Complete DNA sequence of lymphotropic papovavirus: prototype of a new species of the polyomavirus genus. Virology (1985) 2.53
Myosin heavy chain gene expression in human heart failure. J Clin Invest (1997) 2.39
A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods (2001) 2.15
Natural history of HLA expression during tumour development. Immunol Today (1993) 2.04
Randomised trial comparing hysterectomy with endometrial ablation for dysfunctional uterine bleeding: psychiatric and psychosocial aspects. BMJ (1996) 2.00
Monoclonal antibodies as probes for differentiation and tumor-associated antigens: a Forssman specificity on teratocarcinoma stem cells. Cell (1978) 1.97
A viral enhancer element specifically active in human haematopoietic cells. Nature (1985) 1.95
Biochemical engineering of the N-acyl side chain of sialic acid: biological implications. Glycobiology (2001) 1.93
UDP-GlcNAc 2-epimerase: a regulator of cell surface sialylation. Science (1999) 1.88
Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet (1992) 1.80
Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer (2008) 1.77
Is it reality or an illusion that liquid-based cytology is better than conventional cervical smears? Cytopathology (2002) 1.75
Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther (1999) 1.73
Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med (1994) 1.69
Human papillomavirus testing and the outcome of treatment for cervical intraepithelial neoplasia. Obstet Gynecol (2001) 1.60
Somatic diversification of immunoglobulins. Proc Natl Acad Sci U S A (1984) 1.59
Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer (1990) 1.56
Age-restricted cervical screening: HPV testing at age 50 identifies a high risk group for cervical disease. Int J Gynecol Cancer (2002) 1.55
Mutational analysis of the human immunodeficiency virus type 1 env gene product proteolytic cleavage site. J Virol (1990) 1.52
Cervical intraepithelial neoplasia, cervical carcinoma, and risk for patients with HLA-DQB1*0602,*301,*0303 alleles. Lancet (1993) 1.48
Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol (1998) 1.48
Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer (1992) 1.47
A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer (1988) 1.46
A population-based study of microinvasive disease of the cervix--a colposcopic and cytologic analysis. Gynecol Oncol (1992) 1.46
Seropositivity for human papillomavirus and incidence of subsequent squamous cell and basal cell carcinomas of the skin in patients with a previous nonmelanoma skin cancer. Br J Dermatol (2011) 1.45
p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res (1993) 1.45
Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol (2000) 1.43
Identification of inguinal lymph node metastases from vulval carcinoma by magnetic resonance imaging: an initial report. Clin Radiol (2002) 1.43
The laryngeal mask airway. Two cases of prehospital trauma care. Anaesthesia (1992) 1.42
Biosynthetic modulation of sialic acid-dependent virus-receptor interactions of two primate polyoma viruses. J Biol Chem (1995) 1.40
Loss of MHC class-I expression in cervical carcinomas. Int J Cancer (1990) 1.40
Marked differences in Betapapillomavirus DNA and antibody prevalence between patients with psoriasis and those with atopic dermatitis. Br J Dermatol (2011) 1.39
Uterine activity during spontaneous labour after previous lower-segment caesarean section. Br J Obstet Gynaecol (1989) 1.38
Capping of exogenous Forssman glycolipid on cells. J Cell Biol (1979) 1.35
The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway. J Biol Chem (2000) 1.33
Evidence for efficient uptake and incorporation of sialic acid by eukaryotic cells. Eur J Biochem (2001) 1.32
Galactan-binding antibodies. Diversity and structure of idiotypes. J Exp Med (1983) 1.30
Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA. J Virol (1991) 1.29
Expression of a Forssman antigenic specificity in the preimplantation mouse embryo. Cell (1978) 1.28
Theta alloantigen on mouse and rat fibroblasts. Nat New Biol (1973) 1.28
Antibodies against early proteins of human papillomaviruses as diagnostic markers for invasive cervical cancer. J Clin Microbiol (1998) 1.28
Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res (2001) 1.26
Geographical dependence of sequence variation in the E7 gene of human papillomavirus type 16. J Gen Virol (1992) 1.25
Age-related changes in beta-adrenergic neuroeffector systems in the human heart. Circulation (1994) 1.20
Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer (1994) 1.19
The expression of 5T4 antigen in colorectal and gastric carcinoma. Br J Cancer (1992) 1.19
Characterization of the human trophoblast-leukocyte antigenic molecules defined by a monoclonal antibody. J Immunol (1986) 1.19
New cell surface antigens in rat defined by tumors of the nervous system. Proc Natl Acad Sci U S A (1975) 1.15
The cell surface receptor is a major determinant restricting the host range of the B-lymphotropic papovavirus. J Virol (1993) 1.14
A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients. Am J Transplant (2011) 1.13
Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions. Br J Cancer (1993) 1.13
Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer (1995) 1.13
Colposcopy in a family planning clinic: a future model? Br Med J (Clin Res Ed) (1987) 1.12
The case for stopping cervical screening at age 50. Br J Obstet Gynaecol (1997) 1.12
Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell carcinoma. Int J Cancer (2000) 1.12
Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine (2004) 1.11
Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer (2006) 1.11
Specific inhibition of human immunodeficiency virus type 1 replication by RNA transcribed in sense and antisense orientation from the 5'-leader/gag region. Biochem Biophys Res Commun (1990) 1.11
HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer (2011) 1.10
Epstein-Barr virus nuclear antigen 2-estrogen receptor fusion proteins transactivate viral and cellular genes and interact with RBP-J kappa in a conditional fashion. Virology (1995) 1.09
Requirement for expert histopathological assessment of ovarian cancer and borderline tumors. Br J Cancer (2000) 1.08
Five-year follow-up of women with borderline and mildly dyskaryotic cervical smears. Cytopathology (2004) 1.08
Efficacy of cervical-smear collection devices: a systematic review and meta-analysis. Lancet (1999) 1.08
Consequences of a subtle sialic acid modification on the murine polyomavirus receptor. J Virol (1997) 1.08
Fertility and pregnancy outcome following large loop excision of the cervical transformation zone. Br J Obstet Gynaecol (1995) 1.07
Isolation and characterization of 5T4, a tumour-associated antigen. Int J Cancer (1990) 1.06
HPV 16 infection and progression of cervical intra-epithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequence variants. Int J Cancer (1998) 1.06
HLA class II antigen expression in human papillomavirus-associated cervical cancer. Cancer Res (1992) 1.05
TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe. Cancer Lett (2010) 1.05
Serological association of beta and gamma human papillomaviruses with squamous cell carcinoma of the skin. Br J Dermatol (2008) 1.04
Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br J Cancer (2005) 1.04
Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. Cancer Res (1998) 1.04
Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br J Cancer (1994) 1.03
Retracted Single-walled carbon nanotubes-mediated in vivo and in vitro delivery of siRNA into antigen-presenting cells. Gene Ther (2006) 1.03
Tat- and Rev-directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type 1: a temporal analysis. J Virol (1992) 1.02
Mild and moderate dyskaryosis: can women be selected for colposcopy on the basis of social criteria? BMJ (1992) 1.02
Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer (2000) 1.02
Characterization of a new human papillomavirus (HPV 41) from disseminated warts and detection of its DNA in some skin carcinomas. Int J Cancer (1988) 1.02
Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia. Int J Cancer (2000) 1.02
Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int J Cancer (1996) 1.02
Efficient delivery of DNA vaccines using human papillomavirus pseudovirions. Gene Ther (2010) 1.02
Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol (1992) 1.01
Improving stable transfection efficiency: antioxidants dramatically improve the outgrowth of clones under dominant marker selection. Nucleic Acids Res (1998) 1.01
Electrotransfection of human lymphoid and myeloid cell lines. Nucleic Acids Res (1988) 1.01
Biosynthesis of N-acetylneuraminic acid in cells lacking UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase. Biol Chem (2001) 1.00
Differential sialylation of cell surface glycoconjugates in a human B lymphoma cell line regulates susceptibility for CD95 (APO-1/Fas)-mediated apoptosis and for infection by a lymphotropic virus. Glycobiology (1999) 1.00